Claims for Patent: 8,597,655

Summary for Patent: 8,597,655

Title:	Recombinant fusion protein and polynucleotide construct for immunotoxin production
Abstract:	The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.
Inventor(s):	Barnea; Itay (Yavne, IL), Benhar; Itai (Rehovot, IL), Ben-Yosef; Rahamim (Mevaseret-Zion, IL), Vexler; Akiva (Hod Hasharon, IL)
Assignee:	Ramot at Tel-Aviv University Ltd. (Tel Aviv, IL) The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (Tel Aviv, IL) N/A (N/A)
Application Number:	13/239,847
Patent Claims:	1. An immunotoxin, comprising a fusion protein and an anti-ErbB-1 antibody, wherein the fusion protein comprises an immunoglobulin Fc-binding domain and a truncated form of Pseudomonas exotoxin and the fusion protein and the anti-ErbB-1 antibody are non-cross linked. 2. The immunotoxin according to claim 1, wherein the antibody is selected from the group consisting of a monoclonal antibody, a humanized antibody, a chimeric antibody, a single chain antibody, and antigen-binding fragments thereof and is capable of being internalized into the target cell. 3. The immunotoxin according to claim 1, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:1. 4. The immunotoxin according to claim 1, wherein the anti-ErbB-1 antibody is Cetuximab. 5. A composition comprising the immunotoxin of claim 1 and a pharmaceutically acceptable carrier. 6. The immunotoxin according to claim 1, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:1 and the anti-ErbB-1 antibody is Cetuximab. 7. The immunotoxin according to claim 1, wherein the fusion protein comprises a first segment which is an immunoglobulin Fc-binding domain present in multiple copies and a second segment which is a truncated form of Pseudomonas exotoxin, and wherein the first and second segments are joined by a peptide linker. 8. A method for treating a subject afflicted with an ErbB-1 associated cancer, comprising administering to the subject a therapeutically effective amount of a composition comprising an immunotoxin according to claim 1, thereby treating a subject afflicted with an ErbB-1 associated cancer. 9. The method of claim 8, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:1. 10. The method of claim 8, wherein the treating a subject afflicted with an ErbB-1 associated cancer is inducing cell death in cancer cells expressing ErbB-1. 11. The method of claim 8, wherein the antibody is selected from the group consisting of a monoclonal antibody, a humanized antibody, a chimeric antibody, a single chain antibody, and antigen-binding fragments thereof and is capable of being internalized into the target cell. 12. The method of claim 8, wherein the ErbB-1 associated cancer is lung cancer, anal cancer, glioblastoma multiforme, epithelial cancer, prostate cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, renal cancer, or any combination thereof. 13. The method of claim 8, wherein the anti-ErbB-1 antibody is Cetuximab. 14. A method for inducing cell death in a cell expressing ErbB-1, comprising the step of contacting the cell with a therapeutically effective amount of a composition comprising an immunotoxin according to claim 1, thereby inducing cell death in a cell expressing ErbB-1. 15. The method of claim 14, wherein the cell is a cancer cell. 16. The method of claim 14, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:1. 17. The method of claim 14, wherein the antibody is selected from the group consisting of a monoclonal antibody, a humanized antibody, a chimeric antibody, a single chain antibody, and antigen-binding fragments thereof and is capable of being internalized into the target cell. 18. The method of claim 15, wherein the cancer cell expressing ErbB-1 is a lung cancer cell, an anal cancer cell, a glioblastoma multiforme cell, an epithelial cancer cell, a prostate cancer cell, a pancreatic cancer cell, a head and neck cancer cell, a breast cancer cell, an ovarian cancer cell, or a renal cancer cell. 19. The method of claim 14, wherein the anti-ErbB-1 antibody is Cetuximab.

Details for Patent 8,597,655

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2027-05-10
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2027-05-10